Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥259,594 | ¥227,934 | ¥208,859 | ¥165,615 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Cost of Goods Sold | ¥164,865 | ¥146,551 | ¥136,145 | ¥95,429 |
| Gross Profit | ¥94,729 | ¥81,383 | ¥72,714 | ¥70,186 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| R&D Expenses | ¥16,212 | ¥13,242 | ¥15,265 | ¥11,488 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥71,486 | ¥50,494 | ¥51,934 | ¥40,160 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥16,212 | ¥0 | ¥0 | -¥668 |
| Operating Expenses | ¥71,486 | ¥63,736 | ¥67,199 | ¥50,980 |
| Operating Income | ¥23,243 | ¥17,647 | ¥5,514 | ¥19,205 |
| % Margin | 9% | 7.7% | 2.6% | 11.6% |
| Other Income/Exp. Net | ¥3,087 | ¥6,812 | -¥909 | ¥3,041 |
| Pre-Tax Income | ¥26,330 | ¥24,459 | ¥4,605 | ¥22,246 |
| Tax Expense | ¥7,343 | ¥8,286 | ¥2,404 | ¥6,331 |
| Net Income | ¥18,986 | ¥16,173 | ¥2,201 | ¥15,914 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS | 385.7 | 328.58 | 44.72 | 323.35 |
| % Growth | 17.4% | 634.7% | -86.2% | – |
| EPS Diluted | 385.7 | 328.58 | 44.72 | 316.19 |
| Weighted Avg Shares Out | 49 | 49 | 49 | 49 |
| Weighted Avg Shares Out Dil | 49 | 49 | 50 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥221 | ¥97 | ¥17 | ¥8 |
| Interest Expense | ¥1,627 | ¥947 | ¥635 | ¥230 |
| Depreciation & Amortization | ¥20,099 | ¥17,888 | ¥19,409 | ¥10,954 |
| EBITDA | ¥48,055 | ¥35,536 | ¥25,143 | ¥29,492 |
| % Margin | 18.5% | 15.6% | 12% | 17.8% |